Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

The Distinct Roles of CXCR3 Variants and Their Ligands in the Tumor Microenvironment.

Reynders N, Abboud D, Baragli A, Noman MZ, Rogister B, Niclou SP, Heveker N, Janji B, Hanson J, Szpakowska M, Chevigné A.

Cells. 2019 Jun 18;8(6). pii: E613. doi: 10.3390/cells8060613. Review.

2.

Biased antagonism of CXCR4 avoids antagonist tolerance.

Hitchinson B, Eby JM, Gao X, Guite-Vinet F, Ziarek JJ, Abdelkarim H, Lee Y, Okamoto Y, Shikano S, Majetschak M, Heveker N, Volkman BF, Tarasova NI, Gaponenko V.

Sci Signal. 2018 Oct 16;11(552). pii: eaat2214. doi: 10.1126/scisignal.aat2214.

3.

Neuraminidase 1 activates insulin receptor and reverses insulin resistance in obese mice.

Fougerat A, Pan X, Smutova V, Heveker N, Cairo CW, Issad T, Larrivée B, Medin JA, Pshezhetsky AV.

Mol Metab. 2018 Jun;12:76-88. doi: 10.1016/j.molmet.2018.03.017. Epub 2018 Apr 21.

4.

Structure-Activity Relationship Study of Cyclic Pentapeptide Ligands for Atypical Chemokine Receptor 3 (ACKR3).

Sekiguchi H, Kuroyanagi T, Rhainds D, Kobayashi K, Kobayashi Y, Ohno H, Heveker N, Akaji K, Fujii N, Oishi S.

J Med Chem. 2018 Apr 26;61(8):3745-3751. doi: 10.1021/acs.jmedchem.8b00336. Epub 2018 Apr 12.

PMID:
29608300
5.

Different contributions of chemokine N-terminal features attest to a different ligand binding mode and a bias towards activation of ACKR3/CXCR7 compared with CXCR4 and CXCR3.

Szpakowska M, Nevins AM, Meyrath M, Rhainds D, D'huys T, Guité-Vinet F, Dupuis N, Gauthier PA, Counson M, Kleist A, St-Onge G, Hanson J, Schols D, Volkman BF, Heveker N, Chevigné A.

Br J Pharmacol. 2018 May;175(9):1419-1438. doi: 10.1111/bph.14132. Epub 2018 Mar 23.

6.

Ligand-specific conformational transitions and intracellular transport are required for atypical chemokine receptor 3-mediated chemokine scavenging.

Montpas N, St-Onge G, Nama N, Rhainds D, Benredjem B, Girard M, Hickson G, Pons V, Heveker N.

J Biol Chem. 2018 Jan 19;293(3):893-905. doi: 10.1074/jbc.M117.814947. Epub 2017 Nov 27.

7.

Structural basis for chemokine recognition by a G protein-coupled receptor and implications for receptor activation.

Ziarek JJ, Kleist AB, London N, Raveh B, Montpas N, Bonneterre J, St-Onge G, DiCosmo-Ponticello CJ, Koplinski CA, Roy I, Stephens B, Thelen S, Veldkamp CT, Coffman FD, Cohen MC, Dwinell MB, Thelen M, Peterson FC, Heveker N, Volkman BF.

Sci Signal. 2017 Mar 21;10(471). pii: eaah5756. doi: 10.1126/scisignal.aah5756.

8.

Mutational Analysis of Atypical Chemokine Receptor 3 (ACKR3/CXCR7) Interaction with Its Chemokine Ligands CXCL11 and CXCL12.

Benredjem B, Girard M, Rhainds D, St-Onge G, Heveker N.

J Biol Chem. 2017 Jan 6;292(1):31-42. doi: 10.1074/jbc.M116.762252. Epub 2016 Nov 14.

9.

Design, synthesis, and biological evaluation of CXCR4 ligands.

Mona CE, Besserer-Offroy É, Cabana J, Leduc R, Lavigne P, Heveker N, Marsault É, Escher E.

Org Biomol Chem. 2016 Nov 2;14(43):10298-10311.

PMID:
27752700
10.

Structure-Activity Relationship and Signaling of New Chimeric CXCR4 Agonists.

Mona CE, Besserer-Offroy É, Cabana J, Lefrançois M, Boulais PE, Lefebvre MR, Leduc R, Lavigne P, Heveker N, Marsault É, Escher E.

J Med Chem. 2016 Aug 25;59(16):7512-24. doi: 10.1021/acs.jmedchem.6b00566. Epub 2016 Aug 11.

PMID:
27434274
11.

Analysis of Arrestin Recruitment to Chemokine Receptors by Bioluminescence Resonance Energy Transfer.

Bonneterre J, Montpas N, Boularan C, Galés C, Heveker N.

Methods Enzymol. 2016;570:131-53. doi: 10.1016/bs.mie.2015.09.003. Epub 2015 Nov 29.

PMID:
26921945
12.

Development of novel CXC chemokine receptor 7 (CXCR7) ligands: selectivity switch from CXCR4 antagonists with a cyclic pentapeptide scaffold.

Oishi S, Kuroyanagi T, Kubo T, Montpas N, Yoshikawa Y, Misu R, Kobayashi Y, Ohno H, Heveker N, Furuya T, Fujii N.

J Med Chem. 2015 Jul 9;58(13):5218-25. doi: 10.1021/acs.jmedchem.5b00216. Epub 2015 Jun 18.

PMID:
26042340
13.

Mode of binding of the cyclic agonist peptide TC14012 to CXCR7: identification of receptor and compound determinants.

Montpas N, Cabana J, St-Onge G, Gravel S, Morin G, Kuroyanagi T, Lavigne P, Fujii N, Oishi S, Heveker N.

Biochemistry. 2015 Feb 24;54(7):1505-15. doi: 10.1021/bi501526s. Epub 2015 Feb 11.

PMID:
25669416
14.

The chemokine CXC4 and CC2 receptors form homo- and heterooligomers that can engage their signaling G-protein effectors and βarrestin.

Armando S, Quoyer J, Lukashova V, Maiga A, Percherancier Y, Heveker N, Pin JP, Prézeau L, Bouvier M.

FASEB J. 2014 Oct;28(10):4509-23. doi: 10.1096/fj.13-242446. Epub 2014 Jul 22.

PMID:
25053617
15.

Positive regulation of insulin signaling by neuraminidase 1.

Dridi L, Seyrantepe V, Fougerat A, Pan X, Bonneil E, Thibault P, Moreau A, Mitchell GA, Heveker N, Cairo CW, Issad T, Hinek A, Pshezhetsky AV.

Diabetes. 2013 Jul;62(7):2338-46. doi: 10.2337/db12-1825. Epub 2013 Mar 21.

16.

Restoration of renal function by a novel prostaglandin EP4 receptor-derived peptide in models of acute renal failure.

Leduc M, Hou X, Hamel D, Sanchez M, Quiniou C, Honoré JC, Roy O, Madaan A, Lubell W, Varma DR, Mancini J, Duhamel F, Peri KG, Pichette V, Heveker N, Chemtob S.

Am J Physiol Regul Integr Comp Physiol. 2013 Jan 1;304(1):R10-22. doi: 10.1152/ajpregu.00138.2012. Epub 2012 Nov 14.

17.

Structure-based ligand discovery for the protein-protein interface of chemokine receptor CXCR4.

Mysinger MM, Weiss DR, Ziarek JJ, Gravel S, Doak AK, Karpiak J, Heveker N, Shoichet BK, Volkman BF.

Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5517-22. doi: 10.1073/pnas.1120431109. Epub 2012 Mar 19.

18.

Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways.

Drury LJ, Ziarek JJ, Gravel S, Veldkamp CT, Takekoshi T, Hwang ST, Heveker N, Volkman BF, Dwinell MB.

Proc Natl Acad Sci U S A. 2011 Oct 25;108(43):17655-60. doi: 10.1073/pnas.1101133108. Epub 2011 Oct 11.

19.

Agonists for the Chemokine Receptor CXCR4.

Lefrançois M, Lefebvre MR, Saint-Onge G, Boulais PE, Lamothe S, Leduc R, Lavigne P, Heveker N, Escher E.

ACS Med Chem Lett. 2011 Aug 11;2(8):597-602. Epub 2011 Jun 6.

20.

Herpes simplex virus type 1-induced FasL expression in human monocytic cells and its implications for cell death, viral replication, and immune evasion.

Iannello A, Debbeche O, El Arabi R, Samarani S, Hamel D, Rozenberg F, Heveker N, Ahmad A.

Viral Immunol. 2011 Feb;24(1):11-26. doi: 10.1089/vim.2010.0083.

21.

Different effects of the different natural CC chemokine receptor 2b ligands on beta-arrestin recruitment, Gαi signaling, and receptor internalization.

Berchiche YA, Gravel S, Pelletier ME, St-Onge G, Heveker N.

Mol Pharmacol. 2011 Mar;79(3):488-98. doi: 10.1124/mol.110.068486. Epub 2010 Nov 18.

PMID:
21088225
22.

The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains.

Gravel S, Malouf C, Boulais PE, Berchiche YA, Oishi S, Fujii N, Leduc R, Sinnett D, Heveker N.

J Biol Chem. 2010 Dec 3;285(49):37939-43. doi: 10.1074/jbc.C110.147470. Epub 2010 Oct 18.

23.

The activity of the HIV-1 IRES is stimulated by oxidative stress and controlled by a negative regulatory element.

Gendron K, Ferbeyre G, Heveker N, Brakier-Gingras L.

Nucleic Acids Res. 2011 Feb;39(3):902-12. doi: 10.1093/nar/gkq885. Epub 2010 Oct 8.

24.

VRQ397 (CRAVKY): a novel noncompetitive V2 receptor antagonist.

Rihakova L, Quiniou C, Hamdan FF, Kaul R, Brault S, Hou X, Lahaie I, Sapieha P, Hamel D, Shao Z, Gobeil F Jr, Hardy P, Joyal JS, Nedev H, Duhamel F, Beauregard K, Heveker N, Saragovi HU, Guillon G, Bouvier M, Lubell WD, Chemtob S.

Am J Physiol Regul Integr Comp Physiol. 2009 Oct;297(4):R1009-18. doi: 10.1152/ajpregu.90766.2008. Epub 2009 Jul 29.

25.

Photolabeling identifies transmembrane domain 4 of CXCR4 as a T140 binding site.

Boulais PE, Dulude D, Cabana J, Heveker N, Escher E, Lavigne P, Leduc R.

Biochem Pharmacol. 2009 Dec 1;78(11):1382-90. doi: 10.1016/j.bcp.2009.07.007. Epub 2009 Jul 22.

PMID:
19631193
26.

An engineered GM-CSF-CCL2 fusokine is a potent inhibitor of CCR2-driven inflammation as demonstrated in a murine model of inflammatory arthritis.

Rafei M, Berchiche YA, Birman E, Boivin MN, Young YK, Wu JH, Heveker N, Galipeau J.

J Immunol. 2009 Aug 1;183(3):1759-66. doi: 10.4049/jimmunol.0900523. Epub 2009 Jul 10.

27.

Functional selectivity of natural and synthetic prostaglandin EP4 receptor ligands.

Leduc M, Breton B, Galés C, Le Gouill C, Bouvier M, Chemtob S, Heveker N.

J Pharmacol Exp Ther. 2009 Oct;331(1):297-307. doi: 10.1124/jpet.109.156398. Epub 2009 Jul 7.

PMID:
19584306
28.

Positive feedback activation of estrogen receptors by the CXCL12-CXCR4 pathway.

Sauvé K, Lepage J, Sanchez M, Heveker N, Tremblay A.

Cancer Res. 2009 Jul 15;69(14):5793-800. doi: 10.1158/0008-5472.CAN-08-4924. Epub 2009 Jul 7.

29.

HTLV-1 uses HSPG and neuropilin-1 for entry by molecular mimicry of VEGF165.

Lambert S, Bouttier M, Vassy R, Seigneuret M, Petrow-Sadowski C, Janvier S, Heveker N, Ruscetti FW, Perret G, Jones KS, Pique C.

Blood. 2009 May 21;113(21):5176-85. doi: 10.1182/blood-2008-04-150342. Epub 2009 Mar 6.

30.

AMD3100 is a CXCR7 ligand with allosteric agonist properties.

Kalatskaya I, Berchiche YA, Gravel S, Limberg BJ, Rosenbaum JS, Heveker N.

Mol Pharmacol. 2009 May;75(5):1240-7. doi: 10.1124/mol.108.053389. Epub 2009 Mar 2.

PMID:
19255243
31.

Development of a novel noncompetitive antagonist of IL-1 receptor.

Quiniou C, Sapieha P, Lahaie I, Hou X, Brault S, Beauchamp M, Leduc M, Rihakova L, Joyal JS, Nadeau S, Heveker N, Lubell W, Sennlaub F, Gobeil F Jr, Miller G, Pshezhetsky AV, Chemtob S.

J Immunol. 2008 May 15;180(10):6977-87.

32.

Selection of peptides interfering with a ribosomal frameshift in the human immunodeficiency virus type 1.

Dulude D, Théberge-Julien G, Brakier-Gingras L, Heveker N.

RNA. 2008 May;14(5):981-91. doi: 10.1261/rna.887008. Epub 2008 Mar 26.

33.

[Multiple talents of the chemokine receptor-CXCR4].

Desjardins SF, Berchiche YA, Haddad E, Heveker N.

Med Sci (Paris). 2007 Nov;23(11):980-4. French.

34.
35.

Direct assessment of CXCR4 mutant conformations reveals complex link between receptor structure and G(alpha)(i) activation.

Berchiche YA, Chow KY, Lagane B, Leduc M, Percherancier Y, Fujii N, Tamamura H, Bachelerie F, Heveker N.

J Biol Chem. 2007 Feb 23;282(8):5111-5. Epub 2006 Dec 29. Erratum in: J Biol Chem. 2011 Aug 19;286(33):29440.

36.

BRET analysis of GPCR oligomerization: newer does not mean better.

Bouvier M, Heveker N, Jockers R, Marullo S, Milligan G.

Nat Methods. 2007 Jan;4(1):3-4; author reply 4. No abstract available.

37.

G-protein-coupled receptors signalling at the cell nucleus: an emerging paradigm.

Gobeil F, Fortier A, Zhu T, Bossolasco M, Leduc M, Grandbois M, Heveker N, Bkaily G, Chemtob S, Barbaz D.

Can J Physiol Pharmacol. 2006 Mar-Apr;84(3-4):287-97. Review.

PMID:
16902576
38.

Neuropilin-1 is involved in human T-cell lymphotropic virus type 1 entry.

Ghez D, Lepelletier Y, Lambert S, Fourneau JM, Blot V, Janvier S, Arnulf B, van Endert PM, Heveker N, Pique C, Hermine O.

J Virol. 2006 Jul;80(14):6844-54.

39.

Nitric oxide signaling via nuclearized endothelial nitric-oxide synthase modulates expression of the immediate early genes iNOS and mPGES-1.

Gobeil F Jr, Zhu T, Brault S, Geha A, Vazquez-Tello A, Fortier A, Barbaz D, Checchin D, Hou X, Nader M, Bkaily G, Gratton JP, Heveker N, Ribeiro-da-Silva A, Peri K, Bard H, Chorvatova A, D'Orléans-Juste P, Goetzl EJ, Chemtob S.

J Biol Chem. 2006 Jun 9;281(23):16058-67. Epub 2006 Mar 30.

40.

Proangiogenic effects of protease-activated receptor 2 are tumor necrosis factor-alpha and consecutively Tie2 dependent.

Zhu T, Sennlaub F, Beauchamp MH, Fan L, Joyal JS, Checchin D, Nim S, Lachapelle P, Sirinyan M, Hou X, Bossolasco M, Rivard GE, Heveker N, Chemtob S.

Arterioscler Thromb Vasc Biol. 2006 Apr;26(4):744-50. Epub 2006 Jan 26.

PMID:
16439712
41.

Decreasing the frameshift efficiency translates into an equivalent reduction of the replication of the human immunodeficiency virus type 1.

Dulude D, Berchiche YA, Gendron K, Brakier-Gingras L, Heveker N.

Virology. 2006 Feb 5;345(1):127-36. Epub 2005 Oct 25.

42.

[Mystery upon the origin for the selection of AIDS-protective CCR5Delta32].

Janvier S, Heveker N.

Med Sci (Paris). 2005 Jun-Jul;21(6-7):577-9. French. No abstract available.

43.

Tissue factor enhances protease-activated receptor-2-mediated factor VIIa cell proliferative properties.

Fan L, Yotov WV, Zhu T, Esmailzadeh L, Joyal JS, Sennlaub F, Heveker N, Chemtob S, Rivard GE.

J Thromb Haemost. 2005 May;3(5):1056-63.

44.

Bioluminescence resonance energy transfer reveals ligand-induced conformational changes in CXCR4 homo- and heterodimers.

Percherancier Y, Berchiche YA, Slight I, Volkmer-Engert R, Tamamura H, Fujii N, Bouvier M, Heveker N.

J Biol Chem. 2005 Mar 18;280(11):9895-903. Epub 2005 Jan 4.

45.

Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors.

Hartley O, Gaertner H, Wilken J, Thompson D, Fish R, Ramos A, Pastore C, Dufour B, Cerini F, Melotti A, Heveker N, Picard L, Alizon M, Mosier D, Kent S, Offord R.

Proc Natl Acad Sci U S A. 2004 Nov 23;101(47):16460-5. Epub 2004 Nov 15.

46.

Hemofiltrate CC chemokine 1[9-74] causes effective internalization of CCR5 and is a potent inhibitor of R5-tropic human immunodeficiency virus type 1 strains in primary T cells and macrophages.

Münch J, Ständker L, Pöhlmann S, Baribaud F, Papkalla A, Rosorius O, Stauber R, Sass G, Heveker N, Adermann K, Escher S, Klüver E, Doms RW, Forssmann WG, Kirchhoff F.

Antimicrob Agents Chemother. 2002 Apr;46(4):982-90.

47.

Antigenically distinct conformations of CXCR4.

Baribaud F, Edwards TG, Sharron M, Brelot A, Heveker N, Price K, Mortari F, Alizon M, Tsang M, Doms RW.

J Virol. 2001 Oct;75(19):8957-67.

48.

Chemokine receptors as anti-retroviral targets.

Heveker N.

Curr Drug Targets. 2001 Mar;2(1):21-39. Review.

PMID:
11465537
49.

Pharmacological properties of peptides derived from stromal cell-derived factor 1: study on human polymorphonuclear cells.

Heveker N, Tissot M, Thuret A, Schneider-Mergener J, Alizon M, Roch M, Marullo S.

Mol Pharmacol. 2001 Jun;59(6):1418-25.

PMID:
11353801
50.

Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay.

Trouplin V, Salvatori F, Cappello F, Obry V, Brelot A, Heveker N, Alizon M, Scarlatti G, Clavel F, Mammano F.

J Virol. 2001 Jan;75(1):251-9.

Supplemental Content

Loading ...
Support Center